Immunophotonics Signs a Research Agreement with Clinical Laserthermia Clinical Laserthermia Systems for Cancer Patients with Solid Tumors
Shots:
- Immunophotonics and CLS collaborate to evaluate the safety & tolerability of Immunophotonics’ IP-001 in P-Ib/IIa study for cancer patients with solid tumors
- The collaboration will combine CLS’ Immunostimulating Interstitial Laser Thermotherapy (imILT) method & TRANBERG Laser Thermal Therapy System with an intra-tumoral injection of IP-001
- Immunophotonics’ IP-001 is designed to be injected intratumorally followed by an interventional oncology procedure i.e- tumor ablation- inducing a polyclonal T cell response against the cancer
Ref: GlobeNewsWire | Image: Medicon Village
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com